Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fulminant hepatic failure.

S M Riordan1, R Williams

  • 1Institute of Hepatology, University College London, United Kingdom.

Clinics in Liver Disease
|March 10, 2001
PubMed
Summary
This summary is machine-generated.

Advances in supportive medical care have improved outcomes for fulminant hepatic failure (FHF). However, the clinical effectiveness of novel temporary liver support devices and hepatocyte transplantation requires further rigorous evaluation through multicenter trials.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome.

The New England journal of medicine·1992
Same author

Susceptibility to primary biliary cirrhosis is associated with the HLA-DR8-DQB1*0402 haplotype.

Hepatology (Baltimore, Md.)·1992
Same author

Recovery of cholinergic phenotype in the injured rat neostriatum: roles for endogenous and exogenous nerve growth factor.

Journal of neurochemistry·1992
Same author

Immunoglobulin A antibody to a 200-kilodalton cytosolic acetaldehyde adduct in alcoholic hepatitis.

Gastroenterology·1992
Same author

Atrial natriuretic factor in experimental cirrhosis.

Gastroenterology·1992
Same author

Non-modulation as an intermediate phenotype in essential hypertension.

Hypertension (Dallas, Tex. : 1979)·1992
Same journal

Metabolic Dysfunction-Associated Steatohepatitis: From Fibrosis-Based Risk Stratification to Emerging Therapeutic Strategies.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease and Viral Hepatitis.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction Associated Steatohepatitis (MASH) in Oceania, Central America, and the Caribbean.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease in Latin America.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease in Africa: From Burden to Action.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease in Asia: Epidemiology, Clinical Features, and Management.

Clinics in liver disease·2026
See all related articles

Area of Science:

  • Hepatology
  • Regenerative Medicine
  • Critical Care Medicine

Background:

  • Fulminant hepatic failure (FHF) presents significant challenges in patient management and prognosis.
  • Recent advancements include supportive medical measures and innovative temporary liver support devices.
  • The clinical efficacy of these new approaches remains largely unproven.

Purpose of the Study:

  • To assess the current progress and future directions in managing fulminant hepatic failure.
  • To highlight the need for rigorous clinical evaluation of novel liver support technologies.
  • To emphasize the importance of understanding liver regeneration and cell death mechanisms.

Main Methods:

  • Review of recent developments in medical management and technological interventions for FHF.

Related Experiment Videos

  • Discussion of the necessity for controlled multicenter trials with standardized outcome measures.
  • Exploration of research into mechanisms of liver cell death and regeneration.

    • Main Results:

    • Specific medical measures have demonstrably improved FHF prognosis.
    • Promising temporary liver support devices exist, but clinical efficacy is uncertain.
    • Hepatocyte transplantation efficacy in FHF also requires further investigation.

    Conclusions:

    • Controlled multicenter trials are essential for validating liver support devices and hepatocyte transplantation in FHF.
    • Enhanced understanding of liver regeneration and cell death mechanisms is crucial for future targeted therapies.
    • A comprehensive approach combining supportive care, validated technologies, and regenerative strategies is needed for FHF management.